Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $27,556.32 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 614 shares of the business’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $44.88, for a total value of $27,556.32. Following the completion of the sale, the insider now owns 95,034 shares of the company’s stock, valued at approximately $4,265,125.92. This represents a 0.64 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Catriona Yale also recently made the following trade(s):

• On Tuesday, February 18th, Catriona Yale sold 10,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $49.87, for a total transaction of $498,700.00.
• On Monday, December 16th, Catriona Yale sold 9,074 shares of Akero Therapeutics stock. The stock was sold at an average price of $29.11, for a total transaction of $264,144.14.

Akero Therapeutics Trading Down 1.6 %

NASDAQ:AKRO opened at $44.15 on Monday. Akero Therapeutics, Inc. has a 1 year low of $17.86 and a 1 year high of $58.40. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. The stock has a fifty day moving average price of $42.10 and a two-hundred day moving average price of $33.89. The stock has a market capitalization of $3.52 billion, a price-to-earnings ratio of -11.77 and a beta of -0.19.

Akero Therapeutics (NASDAQ:AKRO) last announced its quarterly earnings results on Friday, February 28th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.01). As a group, sell-side analysts anticipate that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Akero Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Summit Investment Advisors Inc. grew its holdings in shares of Akero Therapeutics by 6.8% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,092 shares of the company’s stock worth $197,000 after acquiring an additional 450 shares during the period. Hsbc Holdings PLC boosted its position in Akero Therapeutics by 8.5% during the fourth quarter. Hsbc Holdings PLC now owns 7,886 shares of the company’s stock worth $220,000 after purchasing an additional 621 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Akero Therapeutics by 1.6% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 41,442 shares of the company’s stock valued at $1,153,000 after purchasing an additional 637 shares during the last quarter. Handelsbanken Fonder AB increased its position in shares of Akero Therapeutics by 5.0% in the fourth quarter. Handelsbanken Fonder AB now owns 21,000 shares of the company’s stock valued at $584,000 after buying an additional 1,000 shares in the last quarter. Finally, Swiss National Bank raised its stake in shares of Akero Therapeutics by 1.2% during the 4th quarter. Swiss National Bank now owns 95,600 shares of the company’s stock worth $2,660,000 after buying an additional 1,100 shares during the last quarter.

Analysts Set New Price Targets

A number of research analysts have commented on AKRO shares. Bank of America upgraded shares of Akero Therapeutics from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $35.00 to $63.00 in a research note on Thursday, January 30th. HC Wainwright upped their price objective on Akero Therapeutics from $72.00 to $75.00 and gave the company a “buy” rating in a research note on Monday, March 3rd. Citigroup lifted their target price on Akero Therapeutics from $65.00 to $80.00 and gave the company a “buy” rating in a research note on Tuesday, January 28th. UBS Group upped their price target on Akero Therapeutics from $42.00 to $109.00 and gave the stock a “buy” rating in a research note on Friday, January 31st. Finally, Canaccord Genuity Group lifted their price objective on shares of Akero Therapeutics from $56.00 to $73.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Akero Therapeutics presently has an average rating of “Buy” and a consensus target price of $76.29.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.